September 30, 2022
Loading...
You are here:  Home  >  Banking & Finance  >  Tri-County Public Companies  >  Earnings  >  Current Article

MannKind revenue grows but so does net loss

IN THIS ARTICLE

Revenue continued to climb for MannKind’s inhalable insulin product Afrezza, gaining 35 percent in the fourth quarter to $7.8 million, but net loss rose 46 percent to $14 million during the period. Overall in 2019, the Westlake Village biotech grew sales of Afrezza 46 percent to $25.6 million, slimming net losses by 40 percent to…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.